PLK1 and cancer: However, despite the observations that PLK1 inhibition selectively reduces cell proliferation in cancer cells but not in normal cells, the clinical efficacy of PLK1 inhibitor is limited due to a lack of biomarkers that could be used to stratify patients who will respond to PLK1 inhibitor.